Patients with BRCA1 mutations in breast cancer benefit more from platinum-based protocols than patients with BRCA2 mutations, suggesting that patients with BRCA1 mutations may be more sensitive to platinum-based drug therapy (24). This evidence concerns the gene BRCA2 and breast cancer.